ClinicalTrials.Veeva

Menu
K

Kaohsiung Veterans General Hospital | Department of Allergy, Immunology and Rheumatology

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Guselkumab
TAK-279
SHJ002
Varenicline
HZN-1116
PF-06700841
Obexelimab
Hydroxyurea
Ropeginterferon Alfa-2b
Itraconazole

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 33 total trials

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced sol...

Enrolling
HER2-positive Advanced Solid Tumor
Drug: Itraconazole
Biological: DB-1303/BNT323

The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).

Enrolling
Sjogren's Syndrome
Drug: HZN-1116
Drug: Placebo

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urtic...

Enrolling
Chronic Spontaneous Urticaria
Biological: barzolvolimab
Biological: Matching placebo

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Active, not recruiting
Plaque Psoriasis
Drug: Placebo
Drug: Apremilast

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the...

Active, not recruiting
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo an...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).

Enrolling
Systemic Lupus Erythematosus
Drug: Placebo
Drug: Obexelimab

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoria...

Enrolling
Plaque Psoriasis
Drug: TAK-279

The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (S...

Enrolling
Sjogrens Syndrome
Drug: Placebo
Drug: Standard of care treatment

This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101...

Active, not recruiting
Essential Thrombocythemia
Drug: Anagrelide
Biological: Ropeginterferon alfa-2b

The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.

Active, not recruiting
Nonmetastatic Castration-Resistant Prostate Cancer
Prostate Cancer
Drug: Placebo
Drug: Enzalutamide

Trial sponsors

K
Pfizer logo
Janssen (J&J Innovative Medicine) logo
Amgen logo
Takeda logo
A
B
Boston Scientific logo
Celldex Therapeutics logo
D

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems